| An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses A Harari, PA Bart, W Stöhr, G Tapia, M Garcia, E Medjitna-Rais, S Burnet, ... The Journal of experimental medicine 205 (1), 63-77, 2008 | 365 | 2008 |
| Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 167 | 2008 |
| Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER … S Fidler, W Stöhr, M Pace, L Dorrell, A Lever, S Pett, S Kinloch-de Loes, ... The Lancet 395 (10227), 888-898, 2020 | 119 | 2020 |
| EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone S McCormack, W Stöhr, T Barber, PA Bart, A Harari, C Moog, D Ciuffreda, ... Vaccine 26 (25), 3162-3174, 2008 | 116 | 2008 |
| New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists A Hughes, T Barber, M Nelson Journal of Infection 57 (1), 1-10, 2008 | 92 | 2008 |
| EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium PA Bart, R Goodall, T Barber, A Harari, A Guimaraes-Walker, M Khonkarly, ... Vaccine 26 (25), 3153-3161, 2008 | 77 | 2008 |
| 2016 United Kingdom national guideline on the sexual health care of men who have sex with men D Clutterbuck, D Asboe, T Barber, C Emerson, N Field, S Gibson, ... International journal of STD & AIDS, 0956462417746897, 2018 | 72 | 2018 |
| UK national guideline on safer sex advice DJ Clutterbuck, P Flowers, T Barber, H Wilson, M Nelson, B Hedge, ... International journal of STD & AIDS 23 (6), 381-388, 2012 | 58 | 2012 |
| Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study DL Fink, H Callaby, A Luintel, W Beynon, H Bond, EY Lim, ... The Lancet Infectious Diseases 23 (5), 589-597, 2023 | 54 | 2023 |
| Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study UK CHIC Study Steering Committee, TJ Barber, AM Geretti, J Anderson, ... Antiviral therapy 16 (6), 805-814, 2011 | 46 | 2011 |
| Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial A Winston, J Amin, A Clarke, L Else, A Amara, A Owen, T Barber, ... Clinical Infectious Diseases 60 (7), 1026-1032, 2015 | 38 | 2015 |
| Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor TJ Barber, L Harrison, D Asboe, I Williams, S Kirk, R Gilson, L Bansi, ... Journal of antimicrobial chemotherapy 67 (4), 995-1000, 2012 | 36 | 2012 |
| Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine M Vasylyev, A Skrzat-Klapaczyńska, JI Bernardino, O Săndulescu, ... The Lancet HIV 9 (6), e438-e448, 2022 | 33 | 2022 |
| How health systems can adapt to a population ageing with HIV and comorbid disease J Kiplagat, DN Tran, T Barber, B Njuguna, R Vedanthan, VA Triant, ... The Lancet HIV 9 (4), e281-e292, 2022 | 33 | 2022 |
| HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review R Patel, L Evitt, I Mariolis, S Di Giambenedetto, A d’Arminio Monforte, ... Infectious Diseases and Therapy 10, 2051-2070, 2021 | 33 | 2021 |
| Screening for HIV-related neurocognitive impairment in clinical practice: challenges and opportunities TJ Barber, D Bradshaw, D Hughes, L Leonidou, A Margetts, D Ratcliffe, ... AIDS care 26 (2), 160-168, 2014 | 25 | 2014 |
| Postexposure prophylaxis for HIV following sexual exposure TJ Barber, PD Benn Current Opinion in HIV and AIDS 5 (4), 322-326, 2010 | 25 | 2010 |
| The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age JH Vera, A Jackson, L Dickinson, L Else, T Barber, B Mora-Peris, D Back, ... HIV Clinical Trials 16 (1), 39-42, 2015 | 22 | 2015 |
| Changes in inflammatory and atherogenesis biomarkers with the 2-drug regimen dolutegravir plus lamivudine in antiretroviral therapy–experienced, virologically suppressed people … JM Llibre, PE Cahn, J Lo, TJ Barber, C Mussini, BJ van Welzen, ... Open Forum Infectious Diseases 9 (4), ofac068, 2022 | 21 | 2022 |
| Perceived need of, and interest in, HIV pre-exposure prophylaxis amongst men who have sex with men attending three sexual health clinics in London, UK L Bull, P Dimitrijevic, S Beverley, A Scarborough, S Mandalia, O Dosekun, ... International journal of STD & AIDS 29 (5), 435-442, 2018 | 21 | 2018 |
Deenan PillayVerified email at africacentre.ac.za
